Proteomics International Laboratories Ltd

ASX:PIQ ISIN:AU000000PIQ0

Proteomics International Laboratories LtdProteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

 
 
  

View in Other Languages

News

Proteomics International Laboratories Ltd (ASX:PIQ) Promarker Technology Used For Diagnosing Plant Dieback

🕔5/16/2024 8:17:05 AM 1297

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to confirm the successful collaboration with Curtin University's Centre for Crop and Disease Management (CCDM), with researchers making an important breakthrough in understanding how dieback impacts plants.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) March 2024 Quarterly Activities Report

🕔4/17/2024 8:24:54 AM 1746

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to provide the following update on its business activities for the three months to 31 March 2024.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Investor Presentation

🕔3/28/2024 11:28:09 AM 1868

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to Jefferies Institutional Clients on 28 March 2024.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Signs With Oxford University to Validate Test for Endometriosis

🕔3/25/2024 8:26:03 AM 2207

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce it has signed a Material Transfer Agreement with the globally-respected University of Oxford to acquire approximately 600 patient plasma samples for its endometriosis study.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) PromarkerD US Commercialisation and Promarker Pipeline Update

🕔3/18/2024 9:32:09 AM 2106

Proteomics International Laboratories Ltd (ASX:PIQ) continues to work diligently toward a national launch in the United States of America, of PromarkerD, the Company's innovative predictive test for diabetic kidney disease.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Retains its ISO13485 Certification

🕔3/6/2024 9:53:08 AM 1850

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that is has successfully retained its ISO 13485 certification, an internationally recognised standard for safety and quality management systems in the manufacture of medical devices.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) European Patent Granted for OxiDx Technology

🕔2/28/2024 8:07:34 AM 1848

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce that its subsidiary OxiDx Pty Ltd, has been granted a patent in 19 major European countries for its platform technology to measure oxidative stress.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Investor presentation - Euroz Hartleys Healthcare Forum

🕔2/6/2024 9:21:46 AM 1639

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at Euroz Hartleys Healthcare Forum being held on 6 February 2024.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Study Validates Biomarkers for Endometriosis Blood Test

🕔2/1/2024 9:41:14 AM 1834

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce a milestone for its novel blood test for endometriosis, PromarkerEndo, with the clinical validation of the biomarker panel in an independent patient group.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Study Validates Biomarkers for Oesophageal Cancer Blood Test

🕔2/1/2024 9:40:49 AM 1683

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce a milestone for its novel blood test for oesophageal adenocarcinoma, PromarkerEso, with the clinical validation of the biomarker panel in a second independent patient group.

Read Full Article
###

11,731 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 228) (Last 30 Days: 561) (Since Published: 9872) 

Company Data

    Headquarters
  • QEII Medical Centre
    6 Verdun Street
    Nedlands WA 6009
    Australia
  • Telephone
  • +61-8-9389-1992 
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.proteomics.com.au

Company Reports